Treatment Related Pulmonary Adverse Events Induced by Chemoradiation and Durvalumab Affect Survival in Locally Advanced Non-Small Cell Lung Cancer.

[1]  X. Wang,et al.  Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer , 2022, Frontiers in Immunology.

[2]  D. Planchard,et al.  Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer , 2022, Radiation Oncology.

[4]  F. Lohr,et al.  A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer , 2021, Frontiers in Oncology.

[5]  Jeong Yun Jang,et al.  Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study , 2021, Radiation Oncology.

[6]  F. Lohr,et al.  The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC. , 2021, Clinical lung cancer.

[7]  Young Hak Kim,et al.  Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab. , 2021, Clinical lung cancer.

[8]  Yi-long Wu,et al.  Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  L. Bashoura,et al.  Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications , 2021, Frontiers in Immunology.

[10]  F. Shepherd,et al.  Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. , 2020, European journal of cancer.

[11]  A. Bezjak,et al.  The Clinical Relevance and Management of Grade 2 Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients on Adjuvant Durvalumab , 2020 .

[12]  J. Ahn,et al.  Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. , 2020, Lung cancer.

[13]  K. Kaira,et al.  Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer , 2020, Clinical and translational radiation oncology.

[14]  P. Fu,et al.  Does radiation increase the risk of immunotherapy related pneumonitis in cancer patients with thorax radiotherapy combined immune checkpoint inhibitors: A meta-analysis. , 2020 .

[15]  K. Sanfilippo,et al.  Evaluation of the incidence of pneumonitis in United States veterans with non-small cell lung cancer receiving durvalumab following chemoradiation. , 2020 .

[16]  J. Bradley,et al.  Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer , 2020, Journal of thoracic disease.

[17]  K. Forster,et al.  Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Aerts,et al.  Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[19]  C. Lin,et al.  Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[21]  L. Schwartz,et al.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) , 2018, Journal of Immunotherapy for Cancer.

[22]  W. Shi,et al.  Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition , 2018, Advances in radiation oncology.

[23]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[24]  Radhe Mohan,et al.  Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[26]  S. Formenti,et al.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. , 2017, The Lancet. Oncology.

[27]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[28]  Radhe Mohan,et al.  Clinical Investigation : Thoracic Cancer Functional Promoter Variant rs 2868371 of HSPB 1 Is Associated With Risk of Radiation Pneumonitis After Chemoradiation for Non-Small Cell Lung Cancer , 2022 .

[29]  Radhe Mohan,et al.  Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis. , 2013, International journal of radiation oncology, biology, physics.

[30]  M. Martel,et al.  Radiation dose-volume effects in the lung. , 2010, International journal of radiation oncology, biology, physics.